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Abstract
Burkholderia pseudomallei (BP) and B. mallei (BM) are closely related gram-negative, facultative anaerobic bacteria which
cause life-threatening melioidosis in human and glanders in horse, respectively. Our laboratory has previously generated
and characterized more than 100 mouse monoclonal antibodies (MAbs) against BP and BM, according to in vitro and in vivo
assay. In this study, 3 MAbs (BP7 10B11, BP7 2C6, and BP1 7F7) were selected to develop into chimeric mouse-human
monoclonal antibodies (cMAbs) against BP and/or BM. For the stable production of cMAbs, we constructed 4 major different
vector systems with a dihydrofolate reductase (DHFR) amplification marker, and optimized transfection/selection conditions
in mammalian host cells with the single-gene and/or double-gene expression system. These 3 cMAbs were stably produced
by the DHFR double mutant Chinese hamster ovarian (CHO)-DG44 cells. By ELISA and Western blot analysis using whole
bacterial antigens treated by heat (65uC/90 min), sodium periodate, and proteinase K, the cMAb BP7 10B11 (cMAb CK1)
reacted with glycoproteins (34, 38, 48 kDa in BP; 28, 38, 48 kDa in BM). The cMAb BP7 2C6 (cMAb CK2) recognized surface-
capsule antigens with molecular sizes of 38 to 52 kDa, and 200 kDa in BM. The cMAb CK2 was weakly reactive to 14,28,
200 kDa antigens in BP. The cMAb BP1 7F7 (cMAb CK3) reacted with lipopolysaccharides (38,52 kDa in BP; 38,60 kDa in B.
thailandensis). Western blot results with the outer surface antigens of the 3 Burkholderia species were consistent with results
with the whole Burkholderia cell antigens, suggesting that these immunodominant antigens reacting with the 3 cMAbs
were primarily present on the outer surface of the Burkholderia species. These 3 cMAbs would be useful for analyzing the
role of the major outer surface antigens in Burkholderia infection.
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Introduction
Burkholderia pseudomallei (BP), the causative agent of melioidosis, is
a gram-negative, facultative anaerobic, motile bacillus commonly
found in the soil and stagnant waters[1]. BP infection is often dueto
either direct inoculation into wounds and skin abrasions or
inhalation of contaminated materials [2,3]. The clinical manifesta-
tion ranges from subclinical to acute localized, acute septicemic and
chronic forms [4]. Recently, BP has been recognized as a major
cause of community-acquired septicemia, resulting in significant
mortality [5]. Moreover, numerous studies revealed that BP could
be intrinsically resistant to many antibiotics. Despite therapeutic
regimens with certain antibiotics, the mortality rate of melioidosis
remains very high [6]. B. mallei (BM), a host-adapted pathogen that
does not normally persist in nature, causes glanders in horse. Some
studies indicated that BM is highly infectious in humans by aerosol
route [7]. Thus, there are true concerns that BP and BM may be
used asbiologicalwarfare agents(BWA)[8].Noeffectivevaccinesor
therapeutics of either melioidosis or glanders currently exist.
The only countermeasure providing a state of ‘‘immediate
immunity’’ against these biowarfare agents is neutralizing
antibodies. Unlike vaccines, antibodies can confer passive
protection regardless of the immune status of the infected host.
In comparison with antimicrobial therapy, antibody therapy
against many potential BWAs such as Bacillus anthracis, Francisella
tularensis, and Yersinia pestis is significantly promising due to high
specific function and low toxicity [9]. Currently, specific antibodies
that protect against infections of highly pathogenic BP and BM
that military or civilian populations may encounter in biological
warfares have not been developed. Basic Local Alignment Search
Tool (BLAST) comparisons of the genomes indicated that the
genes conserved between BP and BM are 99% identical at the
nucleotide level [10,11]. The extremely high homology among BP,
BM, and B. thailandensis (BT) would allow for only small window of
antigenic difference among these species of the Burkholderia
bacteria. The main antigenic differences between BP and BM
appeared to reside only in the O-capsular polysaccharides (PS)
moiety of their lipopolysaccharides (LPS) structure. However,
some BM strains might lack the O-PS moiety in their LPS
structure. On the otherhand, different strains of BP were found to
posses LPS with different chemical structure of the O-PS (O-PS I
and O-PS II) [12]. Serological studies also revealed BP and BM
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difficult to obtain a single MAb that can both recognize all
different clinical isolates of BP and at the same time differentiate
them from those of BM as well as BT. Development of MAbs that
can differentiate between all strains of BP and BM from other non-
pathogenic Burkholderia species has been very challenging due to
the close homology. However, if the MAbs developed were to be
used for therapeutic and not diagnostic purposes, MAbs that react
strongly to both BP and BM are highly desirable. Furthermore, to
design therapeutic antibodies for human diseases, it is important
that the selected MAbs react not only to the particular strain of
bacteria used as the immunogen, but to as many different strains
and clinical isolates of these two closely related species of bacterial
pathogens as possible [14,15].
In our previous studies, total 108 mouse MAbs against BP and/
or BM have been generated, characterized, and categorized into 8
groups (from A to H) on their binding patterns against a panel of
11 species of the Burkholderia bacteria and the reactive antigens [PS,
LPS, and (glyco)proteins] recognized by each MAb [16,17]. Most
importantly, many of these MAbs showed good protective efficacy
against both pathogenic Burkholderia bacteria by an in vitro opsonic
assay using differentiated HL-60 cells as phagocytes and in vivo
protective efficacy of selected MAbs against intranasal challenge of
BP and BM in mice. When compared individually, both anti-PS
and anti-LPS MAbs performed better in mouse protection than
the anti-glycoprotein MAbs. Some of these MAbs could potentially
be developed into useful therapeutics in treating the devastating
diseases caused by BP and BM [18]. Other investigators also
showed that the intranasal challenge with a sub-lethal dose of the
bacteria has shown that MAbs against PS, LPS, and glycoproteins
of BP and/or BM significantly reduce lethality of infections in
mice. However, these MAbs fail to achieve full protection,
especially with high dose challenges [19,20].
Development of high-performance cMAbs which could be used
as therapeutics in exposed individuals is urgently needed to fill the
current gap in defense against BWAs. In this study, three major
surface antigen (glycoprotein, PS, and LPS)-reactive MAbs (BP7
10B11, BP7 2C6, and BP1 7F7) against BP and/or BM were
selected to further develop chimeric MAbs (cMAbs) for human
therapeutics. The ultimate goal of this study is to develop
superactive MAbs that can be used as therapeutics against BM
and BP infections. Humanization of the target MAbs could
minimize possible side effects when used as human therapeutics
[21,22]. Therefore, the chimerization of these 3 MAbs against BP
and/or BM is an initial step in the development of MAb-based
therapeutics.
The utilization of bicistronic retroviral expression vectors
containing the gene of interest and an amplifiable marker gene
has been shown as an effective method in obtaining stable cell lines
that express high levels of the cMAb of interest [23–25]. However,
experience with the use of such vectors in high level expression of
cMAbs is currently limited. In this study, to obtain sufficient
quantities of cMAbs, we established a series of technology to
develop cell lines producing of neutralizing cMAbs against BP
and/or BM. This include (i) construction of four major different
mammalian expression vector systems with a dihydrofolate
reductase (DHFR) amplification marker, (ii) optimization of
transfection/selection conditions in Chinese hamster ovarian
(CHO) cells and other common mammalian host cells with the
single-gene (heavy or light chain) vectors and double-gene vector
(both heavy and light chain in the vector) system, (iii) stable cMAb
production by CHO-DG44 cells, and (iv) affinity purification.
These techniques are useful for the development of stable cMAbs
against targeted BWA for therapeutic purposes.
Materials and Methods
Construction of expression vectors with a DHFR
amplifiable marker
To obtain high level expression constructs we modified the
pIRES (Clontech, Palo Alto, CA) vector containing two multiple
cloning sites (MCS) A and B that allows expression of two genes of
interest. Briefly, the PCR-amplified DHFR gene (564 bp) from
mouse cDNA pools was synthesized by a specific primer set
(forward primer with a Sal I site: 59-GCTG CGTCGACCAT-
CATGGTTCGACCATTGAACTGC-39; reverse primer with a
Not I site: 59-GAACTTGAGCGGCCGCAAGCATCTTCTT-
GTTAGTC-39). The DHFR gene (595 bp) was cloned into the
PCR Blunt II-TOPO plasmid using the TA cloning kit
(Invitrogen, Carlsbad, CA) and sequenced. To make the pIRES-
DHFR vector system, the DHFR gene digested with Sal I and Not I
was inserted into MCS-B site separated from MCS-A by an
internal ribosome entry site (IRES) sequence (581 bp) in the
pIRES vector (Fig. 1A).
To generate single-gene vector [pIRES-H(L)-DHFR] systems,
mouse variable regions of the heavy and light chains were
amplified by reverse-transcription PCR (RT-PCR). Total RNA
was extracted from the 3 selected hybridoma clones (BP7 10B11,
BP7 2C6, and BP1 7F7) (5610
6 cells each (Table 1) by TRIzol
reagent (Invitrogen) according to manufacturer’s instruction. For
cDNA synthesis, total cellular RNA (2 mg) was reverse transcribed
as previously described [26]. For PCR, the cDNA (2 ml) was
amplified in a 50-ml reaction mixture containing 16PCR buffer
(10 mM Tris-HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2),
0.2 mM dNTPs, and 0.4 mM (each) primer mixture combinations
with homology to mouse heavy and light chain [For the VH chain:
one set of forward-reverse primer mixture (GE Healthcare,
Piscataway, N.J.); For the VL chain: 6 forward primer and 4
reverse primer mixtures (GE Healthcare)] in a DNA thermal
cycler (BioRad, Hercules, CA). To reduce nonspecific priming, all
PCRs were performed by the hot-start method as previously
described [26]. To identify the consensus sequences of each
variable gene, the target PCR products (VH: 351 bp; VL: 324 bp)
were directly cloned into the PCR4 TOPO vector (Invitrogen) and
their variable sequences were determined by multiple sequence
alignments with mouse antibody sequence data. To introduce the
chimeric heavy or light chains into the MCS-A in the pIRES-
DHFR plasmid, the human constant regions of both chains
(HcG1: 990 bp; HcK: 324 bp) were also amplified from human
cDNA pools using the designed primer sets (HcG1-F: 59-
GCCTCCACCAAGGGCCCATCGG-39 and HcG1-R: 59-TTT-
foACCCGGAGACA GGGAGAGGC-39; HcK-F: 59-CGAACT-
GTGGCTGCACCATCTG-39 and HcK-R: 59-CTAACACT C-
TCCCCTGTTGAAGC-39). After the sequences of all PCR-
amplified products were confirmed, the full-length chimeric heavy
(light) chains were assembled by the overlapping PCR technique.
A freshly prepared full-length chimeric heavy (light) chain was
transformed into the DH5a competent cells (Invitrogen) and
sequences of the plasmid DNAs prepared from more than 10
different clones were confirmed.
To identify the hypervariable loop regions of each chimeric
chain, BLAST search was performed against pre-compiled loop
databases in the Input Protein Molecule (Discovery Studio 2.5; Accelrys,
San Diego, CA). An alignment was created for each loop against its
best hits from the BLAST searches. Multiple sequences of each
chimeric chain were aligned by frame regions (FRs), complemen-
tarity-determining regions (CDRs), and human constant genes
(HcG1 or HcK) using the ClustalW multiple sequence alignment
software, Discovery Studio 2.5 (Accelrys) (Fig. 2).
Chimeric MAbs to Burkholderia
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sites (Nhe Ia t5 9end and EcoR Ia t3 9end), Kozak sequence
(CTCACCATG), synthetic leader sequences [GeneBank access
numbers: H (GU350792); L (GU350793)] derived from consensus
signal sequence of Ig genes, chimeric heavy (light) chain containing
unique restriction sites between junctions [(Xho I-mVH-BsiW I-
HcG1) or Xho I-mVL-BsiW I-HcK)], and stop codon (Fig. 3A). To
construct the p2A-H(L)-DHFR vector system containing the foot
and mouse disease virus (FMDV)-derived 2A self-processing
sequence (APVKQTLNFDLLKLAGDVESNPGP), the cDNA
oligo for 24-amino acid FMDV-2A peptide was synthesized
(Sigma Life Science, Woodlands, TX). The short 2A DNA
sequence (72 bp) was replaced with IRES sequence (581 bp) from
the pIRES-H(L)-DHFR vectors to express cMAbs from a single
open reading frame (Fig. 3B).
To generate the double-gene vector (pH-Fu2A-L-DHFR and
pIRES-L-H-DHFR) systems, which contain both heavy and light
chains in the vector, the DHFR gene at the MCS-B site in both
plasmids (p2A-H-DHFR and pIRES-L-DHFR) was replaced
with the neomycin structural gene in the neomycin cassette. To
construct the pH-Fu2A-L-DHFR plasmid, the furin cleavage site
sequence (RAKR) [27] was added by PCR between the chimeric
heavy chain and the 2A sequence. The full-length cassette [(Nhe I-
Kozak sequence-synthetic leader sequence for the heavy chain-
chimeric heavy chain containing unique restriction sites between
the junctions (EcoR V-mVH-Nru I-HcG1-EcoR I)-Furin cleavage
site (RAKR)-2A sequence-chimeric light chain containing unique
restriction sites between the junctions [(Xho I-mVL-BsiW I-HcK
without Kozak and synthetic leader sequences)-stop codon-Not I)]
was assembled by the overlapping PCR. After the sequence was
confirmed, the full cassette was digested with Nhe I and Not I,
cloned into the prepared p2A-H-DHFR plasmid (DHFR gene at
neomycin cassette) (Fig. 3C, top construct). To make another
double-gene vector system (pIRES-L-H-DHFR) containing IRES
sequences between the junctions of light and heavy chains, after
the pIRES-L-DHFR plasmid was double-digested with Sal I and
Not I, the chimeric heavy chain containing unique restriction sites
between junctions (Sal I-Kozak sequence-synthetic leader se-
Figure 1. Expression system for production of stable cMAbs. (A) The pIRES-DHFR vector was constructed by cloning the modified DHFR gene
into the MCS-B of the pIRES vector. The target chimeric H and L genes were separately cloned into the MCS-A of the pIRES-DHFR vector. (B) Only
mouse variable genes (VH and VL) of the target MAbs (BP7 10B11, BP7 2C6, and BP1 7F7) in each vector were replaced for stable production of cMAbs.
(C) The flow chart shows the key procedures in the development of cMAb producing cells.
doi:10.1371/journal.pone.0019867.g001
Table 1. Three selected hybridoma clones to convert stable cMAbs against BP and BM.
cMAb ID 3 selected hybridomas converted into cMAbs
a Chimeric chain ID
b
Hybridoma
clone ID Antigen injected Isotype Cross-reactivity
Heavy
(mVH+HcG1)
Light
(mVL+HcK)
cMAb CK1 BP7 10B11 BP 430 IgG1/k BP/BM: +;B T :2 H1 L1
cMAb CK2 BP7 2C6 BP 430 IgG2a/k BP/BM: +;B T :2 H2 L2
cMAb CK3 BP1 7F7 BP 8324 IgG3/k BP/BT: +;B M :2 H3 L3
aThese 3 hybridoma clones were selected by their binding specificities, antigen reactivities to their bacterial cell components, and in vitro/vivo neutralizing activities
against B. pseudomallei (BP) 8324 and/or B. mallei (BM) ATCC 23344. BT: B. thailandensis.
bEach chimeric chain was assembled by the overlapping PCR. mVH: mouse variable heavy chain; HcG1: human constant gamma 1; mVL: mouse variable light chain; HcK:
human constant kappa chain.
doi:10.1371/journal.pone.0019867.t001
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into the downstream of IRES sequence (Fig. 3C, bottom
construct).
Optimization of transfection and selection
To determine the optimum plasmid DNA concentration and
most favorable host cells for the transient expression of cMAbs
Figure 2. Multiple sequence alignment of three cMAbs CK1, CK2, and CK3. Sequences of each chimeric chain [(A) heavy chain: H1, H2, and
H3; (B) light chain (L1, L2, and L3)] were ordered by FRs, CDRs, junction between mouse variable gene, and human constant genes (HcG1 and/or HcK)
indicated on the basis of charge difference of amino acids in each chain. GeneBank access numbers: H1 (GU350787), H2 (GU350788), and H3
(GU350789); L1 (GU350790), L2 (GU350791), and L3 (GU350794).
doi:10.1371/journal.pone.0019867.g002
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combined plasmid DNAs (5, 10, 20, and 40 mg) at different molar
ratios (H:L=1:1, 1:2, 1:4, 2:1, 4:1) in a 10-cm culture dish, and 8
common mammalian cells (CHO-K1, CHO-DG44, 293T, COS-
7, BHK-21, SP2, P3636, and IM-9) (Table 2) were used to
optimize transfection conditions using either the lipofectamine
(LF)-2000 or the LF-LTX reagent (Invitrogen). Two days prior to
scheduled transfection, the cells were seeded at 15 ml in a 10-cm
dish at a density of 5610
5 cell/ml in culture media containing
10% dFBS (Invitrogen). For each culture dish to be transfected,
the plasmid DNAs (5, 10, 20, and 40 mg) at different molar ratios
(H:L=1:1, 1:2, 1:4, 2:1, and 4:1) were diluted into 800 ml of Opti-
MEM I without serum. In a separate tube, 80 ml of LF-2000 or
LF-LTX with 10 ml of PLUS reagent (Invitrogen) were diluted
into 720 ml Opti-MEM I medium and incubated for 5 min at
room temperature. The diluted DNAs were combined with the
diluted LF-2000 or LF-LTX reagent, incubated at room
temperature for 30 min to allow DNA-LF reagent complexes to
form. After adding additional 6 ml Opti-MEM I medium to DNA-
lipofectamine complexes (,1,600 ml), the tubes were mixed gently,
and plated onto the 10-cm culture dish prepared. The cells were
incubated at 37uCi naC O 2 incubator for 6 h. Six hours post-
stimulation with the DNA-LF complex in the Opti-MEM I
medium, the cells were washed once with PBS (137 mM NaCl,
10 mM Na2HPO4, 2.7 mM KCl, and 1.8 mM KH2PO4
[pH 7.2]), and changed with the regular culture medium
containing 10% dFBS. The cells were incubated at 37uCi na
CO2 incubator for additional 16 h to recover from any
cytotoxicity from lipofectamine reagents or plasmid DNA itself
freshly prepared from E. coli. After 16-h recovery with the regular
medium supplemented with 10% dFBS, the media was replaced
with the serum-free culture medium. After 72-h incubation, the
culture supernatants were harvested, and the binding properties
and cMAb levels were examined at each condition.
Stable expression of three cMAbs
To develop cell lines producing high levels of 3 cMAbs (CK1,
CK2, and CK3), the DHFR gene-deficient CHO-DG44 cells
obtained from Dr. Larry Chasin (Columbia University) were
propagated in a-MEM with nucleosides and deoxynucleosides
(Invitrogen) supplemented with 10% dFBS (Invitrogen). Two
days before transfection schedule, the cells were trypsinized and
seeded at 15 ml in a 10-cm culture dish at a density of 5610
5
cell/ml in a-MEM media containing 10% dFBS without
Figure 3. Chimeric antibody expression cassettes. (A) Single gene (chimeric heavy or light chain) was linked by IRES sequence in the bicistronic
pIRES-DHFR vectors. (B) Single gene (chimeric heavy or light chain) was linked by FMDV-2A sequence in the bicistronic p2A-DHFR vectors. (C) Two
genes (chimeric heavy and light chain) were linked by FMDV-2A or IRES sequence in the same bicistronic vector.
doi:10.1371/journal.pone.0019867.g003
Chimeric MAbs to Burkholderia
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transfection. For each culture dish to be transfected, the plasmid
DNAs (10 mg each) [H:L molar ratio=1:1 for pIRES-H(L)-
DHFR] into 800 ml of Opti-MEM I without serum were diluted.
In a separate tube, 80 mlo fL F - L T Xw i t h1 0mlo fP L U Sr e a g e n t
was diluted into 720 ml Opti-MEM I medium and incubated for
5 min at room temperature. The diluted DNAs were combined
with diluted LF-LTX reagent and incubated at room tempera-
ture for 25 min to allow DNA-lipofectamine reagent complexes
to form. After adding an additional 6 ml Opti-MEM I medium to
DNA-lipofectamine complexes (1,610 ml), the dishes were mixed
gently, and incubated at 37uCi naC O 2 incubator for a total of
6 h. Twenty four hours post-transfection, the media was
removed, washed once with PBS, and changed with the
DHFR-selection media (a-MEM without nucleosides and deox-
ynucleosides) (Invitrogen) supplemented with 10% dFBS until
they were ready to split. Stable CHO-DG44 cell clones
producing cMAbs against BP or BM were identified by ELISA,
isolated by using cloning cylinders, and amplified in culture
media with increased levels of selective agent methotrexate
(MTX, ICN, Costa Mesa, CA). The stable cell lines expressing
high levels of antibodies were selected and re-tested for their
binding affinity against BP. The selected stable cell clones were
frozen for future large-scale production use.
Production and purification
When stably transfected CHO-DG44 cell lines producing the
selected cMAbs were established by bicistronic vectors containing
the DHFR amplification system, the clones with the highest
expression levels were grown in multiple flasks using serum-free
CHO medium (Invitrogen) to obtain sufficient quantities for
further use. Normally, without MTX amplification, when the
transfected stable cell lines, secreting up to approximately
0.01 pg/cell/day were established, the cMAb-containing medium
was harvested, centrifuged, and filtered (0.45 mm membrane).
To analyze cMAb production levels, the cMAb CK3 transfec-
toma CHO-DG44 cell clone was grown in batch culture to
produce a sufficient amount of cMAb CK3. The supernatant was
harvested after 10 days in batch culture by centrifugation at
3006g for 5 min. The cMAb CK3 supernatant samples were
purified using an A ¨KTAprime plus (GE Healthcare). The cMAb
CK3 purification yield was investigated utilizing an affinity
chromatography resin, a HiTrap rProtein A-Fast Flow column
(GE Healthcare). In brief, samples were loaded and eluted at slow
flow rates ranging from 0.25 to 0.5 ml/min. After direct loading of
culture supernatant (,1 L), the column was washed with 10
column volumes of equilibration buffer (20 mM sodium phosphate
containing 150 mM NaCl, pH 7.5) and eluted in 100 mM glycine
buffer (pH 3.0). The pH of the elution was immediately
neutralized to pH 7.0 using 1 M Tris buffer (pH 10.0). The
pooled cMAb CK3 fraction no. 1-4 (1 ml/tube) was concentrated
and dialyzed in a Slide-A-Lyzer, MWCO 10K (Thermo
Scientific). The cMAb CK3 concentration was measured by the
modified human IgG1 ELISA, stored at 220uC for further use to
examine any changes of their binding to specific Burkholderia
bacterial antigens and their physical properties during humaniza-
tion process from the original mouse MAb BP1 7F7.
Expression analysis of stable cMAb CK3 by CHO-DG44
cells
To examine whether the DHFR gene in the bicistronic pIRES-
H(L)-DHFR vector contributes the increase of cMAb expression,
leading to the high-level production of stable cMAb against BP,
total RNA was extracted from cMAb CK3 transfectoma CHO-
DG44 cells (5610
6 each) cultured for 7 day at different MTX
levels (0, 1, 4, 16, and 64 mM) by TRIzol reagent (Invitrogen).
Total cellular RNA (2 mg) was reverse transcribed as described
previously [26]. The cDNAs (2 ml each) were used to amplify H3,
L3 chain, and DHFR gene including a house keeping hamster b-
actin gene [28] (GeneBank access number: AJ312092) as a control
Table 2. Transient production of the 3 cMAbs by 8 common mammalian host cells
a.
Cell line Description Concn
b (ng/ml)
CK1 CK2 CK3
CHO-K1 Chinese hamster ovarian cell - Used with transient expression and glutamine
synthetase system
370652 357647 434686
CHO-DG44 Chinese hamster ovarian cell - Used for DHFR coamplification to make stable
clones for cMAbs
37663 3 651 7 3 612
293T Transformed human embryonic kidney cell with T antigen - Used for
transient small-scale production
167673 7 634 0 4 645
COS-7 Transformed African green monkey kidney cell -Used for transient small-scale
production
226610 196684 4 1 672
BHK-21 Baby hamster kidney cell - Used for stable gene integration 35673 8 661 7 7 613
Sp2/0-Ag14 Mouse myeloma cell - Used for obtaining hybridoma which produce MAbs
as a fusion partner
,4 ,4 ,4
P3636-Ag8.653 Mouse myeloma cell - Used for obtaining hybridoma which produce MAbs
as a fusion partner
,4 ,4 ,4
IM-9
c EBV-transformed human B-lymphoblast cell – Derived from the blood of a
patient with multiple myeloma
NT
d NT 424657
aThese cell lines were used to select a maximum producer by transient expression using the pIRES-H/L-DHFR vector system. These cells (,10
6 cells/10 cm dish) were
incubated for 72 h after cotransfection with complex mixtures of each pIRES-H (L)-DHFR DNAs (10 mg/dish) and LF-2000.
bCulture supernatants of each cMAb were used to measure the cMAb levels by a modified human IgG1 ELISA. The assay detection limit of cMAb was 4 ng/ml. The
values are the means 6 standard deviations of 3 independent experiments.
cSince the transformed IM-9 cell line has a machinery to produce human IgG/k chain, the antibody levels detected in the assay system were from the majority of
endogenous human IgG/k, not cMAbs.
dNT: Not tested.
doi:10.1371/journal.pone.0019867.t002
Chimeric MAbs to Burkholderia
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CGGCAGCCTCGAGGTGCAGCT GCAGGAGTCAGGGG-
G-39 and H3-R: 59-AAAGGGAAGAATTCGCGGCCGCT-
TATTTACCCGGA GACAGGG-39; L3-F: 59-GATGTCTC-
GAGGACATTGTGCTGACCCAGTC-39 and L3-R: 59-AAAG
GGAAGCGGCCGCGAATTCCTAACACTCTCCCCTGTTG-
A-39; DHFR-F: 59-TCGACCATCATGG TTCGACC-39 and
DHFR-R: 59-GCAAGCATCTTCCTGTTAGT-39; b-actin-F:
59-TCTACAACGA GCTGCG-39 and b-actin-R: 59-CAATT-
TCCCTCTCGGC-39) to examine the effect of DHFR amplifi-
cation on CK3 mRNA expression. PCR was conducted for 30
cycles in all experiments, except for b-actin mRNA (35 cycles).
After PCR, 10 ml of each PCR product was electrophoresed in
1.5% agarose gel containing EtBr. DNA size markers (1 Kb Plus)
were run in parallel. The cMAb CK3 production levels (7-day
culture period) at different MTX concentration were measured by
the modified human IgG1 ELISA.
Treatment of bacteria cells
To analyze reactive antigens by three cMAbs, B. pseudomallei
(BP) 8324, B. mallei (BM) [American Type Culture Collection
(ATCC) 23343, Manassas, VA)], and B. thailandensis (ATCC
700388) were grown separately in Luria-Bertani (LB) medium at
37uC with shaking overnight. Bacterial cells were collected by
centrifugation at 4,0006 g for 10 min. Cells were washed,
resuspended in PBS, and then inactivated at 65uC for 90 min.
Each heat-inactivated whole bacterial sample was quantified by
total protein concentration using BCA reagent (Thermo Scientific,
Rockford, IL). The heat-inactivated Burkholderia bacteria (100 mg
each) [BP 8324, BM ATCC 23344, and BT ATCC 700388] were
divided into 3 micro-tubes. Heat-killed bacteria (BP, BM, and BT)
were prepared by boiling for 10 min. To prepare the sodium
periodate-treated bacteria (BP, BM, and BT), the cells were
incubated with 20 mM sodium periodate in 50 mM sodium
acetate buffer, pH 4.5 for 1 h at room temp in the dark. Following
a brief rinse with 50 mM sodium acetate, the preparation was then
incubated with 50 mM sodium borohydride in PBS for 30 min at
room temp. To prepare the proteinase K-treated bacteria (BP,
BM, and BT), the cells were incubated in 1 mg of proteinase K
(Invitrogen) in 1 ml in distilled water at 60uC for 2 h. After
incubation, 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma,
St. Louis, MO) was added for 10 min, and then bacteria were
washed three times in PBS. Another set of bacteria was treated
with 0.02% SDS to maintain intact bacteria cell morphology.
ELISA
For screening of positive clones by transfection, antibody
quantification, and relative binding analysis, 96-well plates were
coated with heat-killed Burkholderia bacteria at 100 ng of
protein/well in 50 mM Na-bicarbonate buffer (pH 9.6) and
blocked with 5% nonfat dry milk in the same buffer. One
hundred microliters of undiluted (or normalized) cMAb superna-
tant was added to each well, including 100 ml each of both the
positive (cMAb CK3) and negative (normal human serum, Sigma)
controls at 1:10 dilutions in PBS containing 1% BSA in 16PBS.
All plates were incubated at 37uC for 1 h and rinsed three times
with PBS containing 0.05% Tween 20. Peroxidase-conjugated
goat anti-human immunoglobulins (IgG+IgA+IgM; KPL, Gai-
thersburg, MD) at a 1:2000 dilution in 1% BSA in 16PBS were
added and incubated at 37uC for 1 h. Substrate, ABTS system
(KPL) was added and incubated at room temperature for 30 min.
The optical density at 405 nm (OD405) and 492 nm was measured
in an enzyme-linked immunosorbent assay (ELISA) plate reader
(Molecular Device, Sunnyvale, CA). Each assay was repeated
more than twice. The cutoff OD405–492 value for positive reaction
was the mean OD405–492+3 standard deviations of negative control
supernatant. Finally, all positive cells identified as positive clones
by ELISA test were subcultured into six-well culture plates. When
cells were confluent, these clones were frozen in 90% FBS and
10% dimethyl sulfoxide at 285uC. The wells identified as strong
positive clones by primary screening were subcloned three times
via a cloning cylinder or limiting dilution technique.
To quantify cMAb production levels, the capture antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA) against
one human subclass immunoglobulin gamma1 Fc was coated
(1 mg/well in 100 ml of 50 mM sodium carbonate buffer, pH 9.6)
on 96-well ELISA plates. The plates were incubated with blocking
solution (50 mM Tris buffer, pH 8.0 containing 0.14 M NaCl and
1% BSA) for 1 h. Hundred microliters of diluted samples or
human immunoglobulin gamma 1 subclass standards (Sigma) were
incubated in individual wells for 1 hr. The plates were then
incubated with the HRP-conjugated specific IgG1-Fc detection
antibodies (Jackson ImmunoResearch Laboratories) for 1 h. The
plate was washed 5 times with PBS, and then colorized by
substrate ABTS (KPL). The absorbance at 405 nm was measured
on an ELISA plate reader (Molecular Device).
To analyze the binding properties of 3 cMAbs, exponentially
growing bacteria (BP, BM, and BT) were inactivated by incubating
in a 60uC water bath for 90 min. The bacteria were harvested by
centrifugation and washed 6 times with PBS. Heat-killed Burk-
holderia bacteria (100 ng of protein/well) in sodium carbonate
buffer were coated on ELISA plates and blocked with 5% nonfat
dry milk. One hundred microliters of undiluted (or normalized
antibody) supernatant including controls were added in the first row
and serially diluted in a 96-well plate. The plates (100 ml in each
well) were then incubated with the HRP-conjugated goat anti-
human IgG (KPL) for 1 h. The plate was washed with 4 times PBS,
and then colorized by substrate ABTS. The binding activities of 3
cMAbs were examined by their titration curve.
SDS-PAGE and Western blot analysis
Ten micrograms of proteins of heat-killed, sodium periodate-
treated, proteinase K-treated and outer membrane protein (OMP)
fraction of each Burkholderia bacteria (BP, BM, and BT), were
dissolved in sample buffer (5% 2-mercaptoethanol, 10% glycerol,
2% SDS, and 0.08% bromophenol blue in 62.5 mM Tris buffer
[pH 6.8]). Samples, including 10 ml of diluted (1:20) broad range
molecular weight standards (Bio-Rad), were boiled at 100uC for
5 min. SDS-PAGE and Western blotting were performed as
described elsewhere [29]. In brief, protein blots were immersed in
blocking buffer (5% nonfat dry milk in 26PBS) at 4uC overnight
and incubated with culture supernatants (1:10 dilution in blocking
buffer) of cMAbs (CK1, CK2, and CK3) at room temperature for
2 h. After three rinses with TNTT buffer [50 mM Tris-HCl,
150 mM NaCl, 0.02% Tween 20, and 0.01% thimerosal (Sigma),
pH 7.4], the blots were incubated at room temperature for 2 h with
peroxidase-conjugated goat anti-human immunoglobulins (IgG+I-
gA+IgM) (KPL) at a 1:2,000 dilution in blocking buffer. The blots
were washed three times with TNTT buffer for 5 min each. The
peroxidase-positive bands were detected by immersing the blots in a
developing solution 4CN substrate (KPL) for 5 min. The enzyme
reaction was terminated by washing the blots in 0.1 M H2SO4.
Results
Establishment of mammalian expression systems
The three MAbs BP7 10B11, BP7 2C6, and BP1 7F7 were
selected for chimeric engineering [30,31] based on our previous
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19867studies on binding specificity, relative antibody ranking, in vitro
opsonic activity, and mouse protection against BP and/or BM. To
obtain high level expression constructs, we modified the bicistronic
pIRES vector by introducing respective DNAs of chimeric heavy
(light) chains (H1,H3; L1,L3) (Table 1) into the multiple cloning
site (MCS)-A. Into the MCS-B site, separated from the MCS-A by
an IRES sequence, the DHFR gene was inserted to generate the
pIRES-DHFR vector (Fig. 1A). Recently, a new development in
cell transfection technology through the DHFR amplification
allows the highly efficient transfection of mammalian cells relevant
for production of neutralizing cMAbs against BP and/or BM
infection (Fig. 1B). The key challenges in the development of stable
cell lines able to produce cMAbs are summarized in the schematic
chart (Fig. 1C).
To introduce the chimeric heavy or light chains into the MCS-
A in the pIRES-DHFR plasmid, each chimeric fragment
(mVH1,3+HcG1 and mVL1,3+HcK) of the 3 cMAbs CK1,
CK2, and CK3 (Table 1) was assembled by the overlapping
polymerase chain reaction (PCR) technique [32,33] and se-
quenced. Multiple sequences of each chimeric chain were aligned
by FRs, CDRs, junction between mouse variable gene and human
constant genes (HcG1 or HcK) indicated on the basis of charge
difference of amino acids in each chain (Fig. 2). The exact
junctions of FR4 and human constant regions in each chimeric
chain were pinpointed. Amino acid sequence homology data
showed 89.6% sequence identity and 93.6% sequence similarity in
these 3 VH genes originating from the three different hybridoma
clones and 82.9% sequence identity and 89.9% sequence similarity
in the three Vk chains.
To establish a series of technology for production of stable
cMAbs and to evaluate which type of expression vector gives us a
maximum performance for cMAb production, four major different
expression systems with a DHFR amplification marker were
generated by re-engineering the pIRES-DHFR vector. Overall, 6
vectors (4 single-gene vectors pIRES-H(L)-DHFR and p2A-H(L)-
DHFR, and 2 double-gene vectors (pH-Fu-2A-L-DHFR and
pIRES-L-H-DHFR)] (Fig. 3) were constructed to examine their
performance. In brief, the bicistronic pIRES-H(L)-DHFR system
allows translation of two consecutive open reading frames from the
same messenger RNA due to the IRES element between the two
transgenes. Recently, other investigators have reported that a gene
transcribed upstream of the IRES is expressed strongly whereas a
gene placed downstream is expressed at lower levels [34]. Since
the cMAb production using the pIRES-H(L)-DHFR system might
have some limitations- their size and variability in expression of
two genes (cMAb and DHFR), we introduced the respective DNAs
of chimeric heavy (light) chains into only MCS-A, not MCS-B of
the pIRES-DHFR vector (Fig. 3A). Since the self-processing,
FMDV-2A sequence (APVKQTLNFDLLKLAGDVESNPGP:
72 bp) is small sized compared to the internal promoter sequence
with a CMV promoter enhancer (740 bp) or IRES sequence
(581 bp), the 2A mediated co-expression strategy [35] using the
p2A-H(L)-DHFR vectors may be significantly improved over the
approach using the IRES system (Fig. 3B). The main difference
between the single gene vectors and the double-gene vectors (pH-
Fu-2A-L-DHFR and pIRES-L-H-DHFR) is that the amplifiable
DHFR gene of both double-gene vectors is contained in the
neomycin cassette, not in the MCS-B. In the pH-Fu2A-L-DHFR
plasmid, the furin cleavage sequence (RAKR) [27] between the
chimeric heavy chain and the 2A sequence was added to eliminate
potential any adverse effects that might be caused by having a 2A
peptide residue on our cMAbs due to incomplete cleavage of 2A-
mediated heavy chain, which might lead to a significant decrease
of cMAb production levels.
Another double-gene vector system (pIRES-L-H-DHFR) con-
tains IRES sequences between the junctions of light (at MCS-A)
and heavy (at MCS-B) chains (Fig. 3C). The unique restriction
sites between the junctions in all eight vectors, sequences for
synthetic leader and Kozak (except for the pH-Fu2A-L-DHFR
vector) were also included to facilitate the vector engineering for
future use of any drug candidates such as recombinant vaccines or
proteins. Although these vector systems offer many unique
qualities and advantages, the three single-gene vector systems
were basically used for cotransfection of the two vectors (heavy and
light chain) into the mammalian host cells, while the two double-
gene vectors were used for single gene transfer.
Optimization of transfection and selection
In a transient expression condition, we have predetermined the
optimum transfection conditions [DNA concentration (total
10 mg/10-cm culture dish), molar ratios (H:L=1:1 or 1:2) (data
not shown), use of lipofectamine (LF)-LTX reagent, and CHO-K1
cells among eight different host cells tested]. To further develop
into the stable production of 3 cMAbs, not transient production,
the CHO double deletion mutant (dhfr
2/dhfr
2) CHO-DG44 cells
were transfected using a LF-LTX containing the PLUS reagent at
a high cell density (more than 90% confluent in a 10-cm culture
dish). The best results in transfection efficiency (60–90%) and
positive selection through a step-wise DHFR amplification process
were obtained, suggesting that the LF-LTX reagent is less toxic to
the cells than the LF-2000 reagent, and the use of highly confluent
cells in the culture dish had better chance to recover 16 h post-
transfection due to close contact of adjacent cells in a 10 cm-
culture dish. After more than 30 positive clones were identified by
ELISA and cultured in a DHFR selective medium containing
0.005 mM MTX, the top 5 highest producers were further selected
for the next amplification step after regaining their polygonal
morphology (2–3 weeks). Although the concentration of MTX in
our initial plan was expected to increase from 0.005 mMt o8 0mM
(4 times increase in each step), we found that the longer-incubation
periods at high dose of MTX levels (.64 mM) resulted in
decreased cMAb production level due to slowed growth rates.
Therefore, these three cMAb producing stable clones were
amplified only until 2 mM MTX levels for increase of cell growth
rate and reduction of cell cytotoxicity in the final products.
Binding activity of 3 cMAbs
To examine the most suitable host cells for cMAb production by
the pIRES-H(L)-DHFR vector systems, the cMAbs were tran-
siently produced by 8 different mammalian host cells using a LF-
2000 reagent. Five days after the transfection, the antibody
production levels were measured by the human IgG1 ELISA. The
MAb CK3 produced by COS-7 and 293T cells showed strong
antibody titers (1:256; 1:128) (Fig. 4A) and higher production
levels (,400 ng/ml) than those levels produced by 6 different cells
tested (Table 2).
Next, to test the re-engineered vector performance, the MAb
CK3 was transiently produced by CHO-K1 cells using the LF-
LTX reagent. The cMAb CK3 by the bicistronic single gene
vectors [pIRES-H(L)-DHFR and p2A-H(L)-DHFR] had strong
binding properties compared to stable cMAb CK3 at 2 mM MTX
levels and transient cMAb CK3 by other 2 double gene vectors
(Fig. 4B). The cMAb CK3 by CHO-K1 cells co-transfected by
either the p2A-H(L)-DHFR or the pIRES-H(L)-DHFR vectors
using a LF-LTX reagent showed a strong binding activity against
BP (Fig. 4B) and reached high production levels (1,049 and
694 ng/ml, respectively) compared to two other systems (Table 3).
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CK1, CK2, and CK3) produced by transfectoma CHO-DG44
cells using the pIRES-H(L)-DHFR vector system, the undiluted 3-
day culture supernatant without DHFR amplification was titrated
by ELISA using the heat-killed BP antigen. The result indicated
that the cMAb CK3 showed a strong binding activity to BP over
cMAbs CK1 and CK2 (Fig. 4C). The master seed cells were
further incubated for 14 days in DHFR selection medium [(a-
MEM without added nucleosides and dialyzed fetal bovine serum
(dFBS)] to isolate the highest producers using cloning cylinders
before entering the amplification process by MTX.
We also compared the binding property of the affinity-purified
cMAb CK3 with the original mouse MAb BP1 7F7 by adjusting to
the same concentration starting with 5 mg/ml. The binding affinity
between the MAb CK3 and the MAb BP1 7F7 was not
significantly changed from the dilutions 1:1 to 1:160, thereafter
the slope of the cMAb CK3 titration curve was slightly dropped
Figure 4. Binding activity of cMAbs produced by mammalian cells with different vector systems. (A) Selection of suitable host cells for
transient production of cMAbs. The cMAb CK3 was transiently produced by 8 different mammalian host cells (,5610
6 cells each/10 cm dish) for 5
days post-transfection using a LF-2000 reagent. The undiluted supernatants including a control (supernatant from CHO-K1 cells transfected by only
pIRES-DHFR vector without chimeric chains), were used for cMAb CK3 titration. The number in the parenthesis mark indicates the cMAb CK3 titer.
(B) Performance of the re-engineered vector systems for cMAb CK3 production was evaluated by CHO-K1 cells transfected using a LF-LTX reagent.
Five days post-transfection of the vectors (10 mg) into the cells (,1610
6 cells/10 cm dish), the undiluted supernatants were used for cMAb CK3
titration, including controls (stable cMAb CK3* at 2 mM MTX: pIRES-H3-DHFR/pIRES-L3-DHFR and culture supernatant by only pIRES-DHFR vector). (C)
Binding property of 3 cMAbs produced by CHO-DG44 cells without DHFR amplification. For ELISA, the pIRES-H(L)-DHFR vectors containing chimeric
H-chain (H1, H2, and H3) or L-chain (L1, L2, and L3) were cotransfected into CHO-DG44 cells (,10
6 cells/10 cm dish) using a LF-2000 reagent and the
master seed cells were incubated for 3 days to get sufficient amounts of cMAbs before the DHFR-amplification process. (D) Comparison of binding
property of stable cMAbs with the original mouse MAbs. Affinity-purified antibodies were adjusted to the same concentration starting with 5 mg/ml.
doi:10.1371/journal.pone.0019867.g004
Table 3. Production of cMAb CK3 using different expression
vectors with a DHFR gene
a.
Expression system cMAb CK3
Concn
b (ng/ml)
pIRES-H3-DHFR/pIRES-L3-DHFR 694614
p2A-H3-DHFR/p2A-L3-DHFR 1,049621
pH3-Fu2A-L3-DHFR 4861
pIRES-L3-H3-DHFR 4261
aTo evaluate the expression performance using 5 different vector systems, each
construct was transfected into CHO-K1 cells (,10
6 cells/10 cm dish) using a LF-
LTX reagent. The cells were incubated for 72 h.
bCulture supernatants were used to measure cMAb CK3 levels by the ELISA. The
values are the means 6 standard deviations of 3 independent experiments.
doi:10.1371/journal.pone.0019867.t003
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slight loss of binding activity to the BP antigen may be due to the
differences in antibody assembly and post-translational modifica-
tion between two host cells (CHO-K1 and hybridoma) during the
chimerization process from the original mouse hybridoma BP1
7F7.
Production and purification of cMAb CK3 to examine
cMAb quality
The cMAb production levels by 8 different host cells and 4
different constructs are summarized in Table 2 and 3. Overall, the
use of bicistronic pIRES-H(L)-DHFR expression vectors, contain-
ing the gene of either chimeric heavy or light chain upstream of
the DHFR amplifiable marker, was effective in obtaining high
levels of the transient cMAb produced by using CHO-K1 cells.
The production levels (1,049 ng/ml) of a bicistronic vector based
on 2A sequence was ,1.5 times greater than that (694 ng/ml) of
an IRES based vector.
For purification and purity analysis of cMAb CK3, the pooled
CK3 supernatant samples (,1 L) were purified by the A ¨KTA-
prime plus using an affinity chromatography column (HiTrap
rProtein A-FF). The cMAb CK3 chromatogram consisted of the
binding, flow-through, and elution (Fig. 5). The pooled cMAb
fractions were dialyzed and purification yields were evaluated by
the modified human IgG1 ELISA. The purity of cMAb CK3 was
analyzed by SDS-10% polyacrylamide gel electrophoresis (PAGE).
Analysis by ELISA and gel electrophoresis showed that cMAb
CK3 was recovered at purity and final yield of 92–96% from the
HiTrap rProtein A-FF column. The A ¨KTAprime was operated by
slow flow-rate (0.25–0.5 ml/min) and pH of binding buffer
(20 mM sodium phosphate containing 150 mM NaCl, pH 7.5)
for successful purification of cMAb CK3. Since the purity of
cMAb obtained from HiTrap rProtein A-FF column was high, the
ability to withstand high column pressures and nearly 95%
recovery of the original supernatant antibody made a HiTrap
rProtein A-FF column well suited as an initial capture step without
a further polishing step. These results also indicated that cMAb
CK3 was appropriately produced by CHO-DG44 cells through
our expression systems and were heterodimeric form with a right
size Fc tail necessary for binding to protein A column.
Expression analysis of cMAb CK3
Since we hypothesized that the amplifiable DHFR gene in the
expression vector contributes to the increased amount of antibody
Figure 5. Affinity purification and purity analysis of cMAb CK3. For purification and purity analysis of cMAb, the pooled cMAb CK3
supernatant samples (,1 L) were purified by the A ¨KTAprime plus using an affinity chromatography column (HiTrap rProtein A-FF). The pooled cMAb
fractions were dialyzed and purification yield were evaluated by the modified human IgG1 ELISA. The purity of cMAb CK3 was analyzed by the SDS-
10% PAGE.
doi:10.1371/journal.pone.0019867.g005
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cMAb, the effect of DHFR amplification on mRNA expression
and cMAb CK3 production levels was examined by RT-PCR and
ELISA. The results showed the dose-dependent upregulation of
mRNAs (chimeric H3- and L3-chains, and DHFR) (Fig. 6A) and
cMAb CK3 production levels (starting above 400 ng/ml without
DHFR amplification) (Fig. 6B) at a 4-fold increase of MTX levels
(0, 1, 4, 16, and 64 mM) for 7 days. In the stable CHO-DG44 cells,
both the cMAb CK3 mRNA expression and production levels
were increased in a MTX dose-dependent manner suggesting that
the DHFR system would be useful for overproduction of
therapeutic MAbs [36].
Reactive antigen analysis by three cMAbs
Three Burkholderia (BP 8324, BM ATCC 23344, and B.
thailandensis (BT) ATCC 700388) species were used to test their
binding specificities to 3 cMAbs (cMAbs CK1, CK2, and CK3),
and the antigen reactivities to their bacterial cell components by
ELISA and Western blot analysis using treated whole bacterial
antigens [heat, sodium periodate [37] (to detect cMAb specific for
carbohydrate epitopes using a periodate oxidation), proteinase K,
0.02% sodium dodecyl sulfate (SDS), and OMP fractions. ELISA
data (Fig. 7) and Western blot results (Fig. 8) showed that the
cMAb CK1 reacted with glycoproteins (22–28, 38, 48, 55 kDa in
BP and BM). The cMAb CK2 recognized capsular polysaccharide
antigens with molecular sizes of 37 to 51 kDa, and 200 kDa in
BM. The cMAb CK2 was slightly reactive to 14–28 kDa and
200 kDa protein in BP. The cMAb CK3 reacted with typical LPS-
like antigens (34, 38–52 kDa in BP or 34, 38–60 kDa in BT)
(Fig. 7B, Table 4). Since mild treatment of the bacteria cells with
0.02% SDS could maintain bacterial membrane rigidity without
cell disruption, the antibody reactivity to these epitopes had no
significant differences compared to the heat-killed Burkholderia
(Fig. 7). Western blot results with the OMP fraction of the 3
Burkholderia species were consistent with results of whole
Burkholderia cell antigens (Fig. 8).
Discussion
In this study, we developed a series of technology for production
of stable cMAbs against BP and/or BM by CHO-DG44 cells using
the DHFR expression systems. Overall, we have generated six
mammalian expression vectors, incorporating IRES and FMDV-
2A sequences that efficiently mediated the (co)expression of two
transgenes in multiple mammalian cell types. These vectors are
useful for various cMAb productions in the laboratory. In our
present study, the utilization of either bicistronic pIRES-H(L)-
DHFR or p2A-H(L)-DHFR vectors has been shown as the most
effective method in obtaining stable cell lines that express high
levels of the cMAbs. Therefore, two systems utilizing single gene
vectors might be more relevant than other systems for maintaining
intact binding properites after chimerization and higher level
production of cMAbs by mammalian host cells.
Recent progresses in antibody engineering, cell transfection
technology, and expression systems containing selective markers
allow highly efficient transfection of mammalian cells for the fast
production of neutralizing cMAbs [31,38] The efficient transfec-
tion of cells not only facilitates stable cell clone generation, but also
allows true preclinical development of cMAb production in
transiently transfected cells for small-scale production. Using the
CHO double deletion mutant (dhfr
2/dhfr
2) CHO-DG44 cells,
we were able to amplify the chimeric antibody gene associated
with the amplifiable DHFR gene by systematic increases of MTX
in medium without added nucleosides. For the development of
therapeutic cMAbs, it is critical to obtain a thoroughly guaranteed
stable clone derived from a single clone producing stable cMAbs.
Using the bicistronic pIRES-H(L)-DHFR vector system, approx-
Figure 6. Dose-dependent upregulation of mRNAs (chimeric H3- and L3-chains, and DHFR) and cMAb CK3 production levels by
stable CHO-DG 44 CK3 cells at different MTX levels. (A) mRNA (H3, L3, and DHFR genes) expression in the stable CHO-DG44 CK3 cells at the 4-
fold increase of MTX levels (0, 1, 4, 16, and 64 mM) for 7 days. DNA size markers (1 Kb plus fragments) are shown at the left. The data presented are
representative of 3 independent experiments that gave similar results. (B) MTX dose-dependent cMAb CK3 production by the stable CHO-DG44 at
different MTX levels. The amounts of cMAb from CHO-DG44 cells (5610
6 cells) were measured by the modified human IgG1 ELISA.
doi:10.1371/journal.pone.0019867.g006
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amplification and adaptation to serum-free conditions. By using
cloning cylinders and applying a less toxic lipofectamine (LF-LTX)
reagent to the highly confluent CHO-DG44 cells (,90%), we
significantly reduced the time and increased the probability of
finding the positive clone. Although tedious time is still required
for these procedures, the end-results obtained through the
selection/amplification processes allow us to use stable cMAbs.
Considering the production levels and binding properties of
cMAbs produced by transient transfection using 8 different
mammalian host cells, the cell lines (CHO-K1, COS-7, 293T,
and BHK-21) were more productive than other mammalian cells
tested. However, for large-scale production, the CHO-DG44 cells
are only available in obtaining stable clones due to the property of
deficient DHFR genes within host chromosomes. Thus, we can
continuously amplify the target antibody gene up to certain MTX
levels without causing any cell damage. When producing
therapeutic cMAb, the CHO-DG44 cell line makes an ideal cell
factory since their cMAbs largely correspond to genuine human
MAbs with similar patterns of post-translational modification and
glycosylation [38]. The availability of commercial media of high
quality for cell culture is an additional factor that would support
large-scale production of cMAbs in this cell line.
Recent studies of the role of Burkholderia outer surface antigens in
mouse protection by using MAbs post-nasal or lethal challenges of
pathogenic Burkholderia species indicate that the Burkholderia
Figure 7. Reactive antigen analysis of 3 cMAbs using the treated-Burkholderia bacteria antigens. Three Burkholderia (BP 8324, BM ATCC
23344, and BT ATCC 700388) species were used to test the binding specificities of the anti-Burkholderia (cMAbs CK1, CK2, and CK3), and the antigen
reactivities of the cMAbs to bacterial cell components. The cMAbs and normal human serum (NS: a negative control) were adjusted to the same
concentration (5 mg/ml).
doi:10.1371/journal.pone.0019867.g007
Figure 8. Western immunoblot analysis of BP, BM, and BT with 3 cMAbs. (A) Proteins were separated on an SDS-10% polyacrylamide gel
and stained with Coomassie blue. (B) For Western blot analysis, 3 cMAb culture supernatants (cMAbs CK1, CK2, and CK3) were used at 1:5 dilutions.
Molecular weight (MW) standards were from Bio-Rad.
doi:10.1371/journal.pone.0019867.g008
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potential protective antigenic targets [39–43]. Our ELISA data
and Western blot analysis, using the treated antigens (heat, sodium
periodate, proteinase K, and 0.02% SDS) and OMPs antigens of 3
Burkholderia species, revealed each cMAb’s reactivity to bacterial
cell components and immunodominant antigens with different
molecular size from 21 kDa to 65 kDa. Briefly, due to different
antigen reactivities (cMAb CK1: surface glycoproteins of BP and
BM; cMAb CK2: capsular polysaccharide antigens of BP and BM;
cMAb CK3: surface LPS and/or lipoproteins (LP) of BP and BT),
these 3 cMAbs would be useful for neutralizing BP and/or BM
infection and studying the role of the major surface antigens in
Burkholderia infection. Furthermore, since LP is a major
component of the outer membrane of gram-negative bacteria,
LP in culture supernatants of growing Burkholderia cells may
induce pathologic changes associated with infections [44]. Our
previous studies of in vitro neutralization and antibody ranking
using the original mouse MAbs suggest that the surface epitopes
(with little cross-reactivity to other Burkholderia bacteria)
recognized by these 3 cMAbs are highly specific to target
Burkholderia species. Thus, these cross-reactive antigens in 3
Burkholderia species may be useful for determining potential vaccine
targets against Burkholderia infection.
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